EVOX THERAPEUTICS
Live / Applied — Opposition pending (as of 21 May 2025)
What this means for you
Not registered yet, but its 01 Dec 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79359336
- Mark type
- Stylized text
- Filed
- 01 Dec 2022
- Published for opposition
- 21 Jan 2025
- Attorney of record
- LAURA POPP ROSENBERG
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, drug delivery agents in the form of exosomes consisting of compounds that facilitate the delivery of a wide range of pharmaceutical preparations; pharmaceutical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use, namely, for the release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, engineered exosomes to deliver pharmaceutical preparations in the nature of protein for genetic therapy; medicine, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations for medical purposes, namely, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosomes, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising a therapeutic target protein-loaded exosome that facilitates the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising exosomes for pharmaceutical purposes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological reagents for medical use, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; mixed biological preparations for medical purposes, namely, for the prevention and treatment of infectious diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or infectious diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies, namely, mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; all of the foregoing excluding such goods in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes
- Class 042 — Scientific and technological services: Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; all of the foregoing excluding such services in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes
Owner
Prosecution history
- 21 Jun 2025 — REFUSAL PROCESSED BY IB
- 21 May 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 21 May 2025 — OPPOSITION INSTITUTED NO. 999999
- 20 May 2025 — OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
- 20 May 2025 — OPPOSITION NOTICE (IB REFUSAL) CREATED
- 30 Jan 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 21 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jan 2025 — PUBLISHED FOR OPPOSITION
- 15 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 26 Dec 2024 — EXPARTE APPEAL TERMINATED
- 23 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Dec 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Dec 2024 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 20 Dec 2024 — EX PARTE APPEAL-INSTITUTED